MX2017012220A - Composiciones adyuvantes y metodos relacionados. - Google Patents
Composiciones adyuvantes y metodos relacionados.Info
- Publication number
- MX2017012220A MX2017012220A MX2017012220A MX2017012220A MX2017012220A MX 2017012220 A MX2017012220 A MX 2017012220A MX 2017012220 A MX2017012220 A MX 2017012220A MX 2017012220 A MX2017012220 A MX 2017012220A MX 2017012220 A MX2017012220 A MX 2017012220A
- Authority
- MX
- Mexico
- Prior art keywords
- adjutive
- compositions
- related methods
- composition
- adjuvant composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- 239000002671 adjuvant Substances 0.000 abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 1
- 229930182490 saponin Natural products 0.000 abstract 1
- 150000007949 saponins Chemical class 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente descripción proporciona una composición adyuvante que es adecuada para administración inyectable, así como transdérmica. La composición adyuvante, en general, comprende un lipófilo, un polímero de ácido acrílico o metacrílico, solución salina, colesterol, una saponina e hidróxido de sodio. También se proporciona una composición de vacuna que incluye, en general, la composición de vacuna de la presente descripción y un componente de ADN. También se proporciona un método de vacunación de animales y humanos que utiliza la composición adyuvante de la presente descripción.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562137659P | 2015-03-24 | 2015-03-24 | |
| PCT/US2016/024003 WO2016154432A1 (en) | 2015-03-24 | 2016-03-24 | Adjuvant compositions and related methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017012220A true MX2017012220A (es) | 2018-02-09 |
| MX390860B MX390860B (es) | 2025-03-21 |
Family
ID=56973861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012220A MX390860B (es) | 2015-03-24 | 2016-03-24 | Composiciones adyuvantes y metodos relacionados. |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9636397B2 (es) |
| EP (1) | EP3273950A4 (es) |
| JP (1) | JP6925277B2 (es) |
| AU (1) | AU2016235059B2 (es) |
| CA (1) | CA2979556C (es) |
| MX (1) | MX390860B (es) |
| WO (1) | WO2016154432A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10195261B2 (en) | 2014-11-26 | 2019-02-05 | VaxLiant, LLC | Adjuvant compositions and related methods |
| AU2016235059B2 (en) | 2015-03-24 | 2021-04-01 | Huvepharma, Inc. | Adjuvant compositions and related methods |
| GB201616904D0 (en) * | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
| US11197928B2 (en) | 2017-01-13 | 2021-12-14 | Board Of Regents, The University Of Texas System | Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate |
| EP3630175A4 (en) | 2017-05-31 | 2021-03-17 | Texas Tech University System | METHOD AND DEVICE FOR TREATMENT OF FOOD ALLERGIES |
| WO2019145475A2 (en) | 2018-01-25 | 2019-08-01 | Acm Biolabs Pte Ltd | Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof |
| US11813321B2 (en) * | 2018-07-13 | 2023-11-14 | Biomune Company | Vaccines against avian reoviruses |
| CN112996539A (zh) | 2018-09-12 | 2021-06-18 | Acm生物实验室私人有限公司 | 包含共价结合的抗原的聚合物囊泡以及其制备方法和用途 |
| WO2021019102A2 (en) | 2019-08-01 | 2021-02-04 | Acm Biolabs Pte Ltd | A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes |
| US20230256082A1 (en) | 2020-04-24 | 2023-08-17 | Acm Biolabs Pte Ltd | Vaccine against human-pathogenic coronaviruses |
| US20240299528A1 (en) * | 2020-07-03 | 2024-09-12 | Statens Serum Institut | A dna plasmid sars-corona virus-2/covid-19 vaccine |
| WO2022123070A1 (en) | 2020-12-11 | 2022-06-16 | Acm Biolabs Pte Ltd | Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant |
| WO2022167497A1 (en) | 2021-02-02 | 2022-08-11 | Acm Biolabs Pte Ltd | Sole use of polymersome associated adjuvant for stimulating an immune response |
| CA3214934A1 (en) | 2021-04-12 | 2022-10-20 | Madhavan Nallani | Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof |
| CN113913395B (zh) * | 2021-10-19 | 2022-06-14 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 人工重组的h5n8流感病毒及其制备方法和应用 |
| US20250235532A1 (en) | 2022-02-23 | 2025-07-24 | Acm Biolabs Pte Ltd | Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| US20080292663A1 (en) * | 2007-05-22 | 2008-11-27 | Gerber Jay D | Adjuvant compositions and methods for delivering vaccines |
| CN104758929B (zh) * | 2008-06-27 | 2018-05-25 | 硕腾有限责任公司 | 新颖的佐剂组合物 |
| CN102105133B (zh) * | 2008-07-21 | 2015-06-17 | 奥德纳米有限公司 | 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法 |
| US20110207952A1 (en) * | 2010-02-22 | 2011-08-25 | Rafael Avila | Cholesterol extraction from algae and preparation of vegan vitamin d3 |
| WO2013138334A1 (en) * | 2012-03-12 | 2013-09-19 | Advanced Bioadjuvants, Llc | Adjuvant and vaccine compositions |
| CN104769112A (zh) | 2012-11-01 | 2015-07-08 | 菲克特生物科学股份有限公司 | 用于在细胞中表达蛋白质的方法和产品 |
| PL3223846T3 (pl) * | 2014-11-26 | 2024-03-11 | Huvepharma, Inc. | Kompozycje adiuwantowe i powiązane sposoby |
| US10195261B2 (en) | 2014-11-26 | 2019-02-05 | VaxLiant, LLC | Adjuvant compositions and related methods |
| AU2016235059B2 (en) * | 2015-03-24 | 2021-04-01 | Huvepharma, Inc. | Adjuvant compositions and related methods |
-
2016
- 2016-03-24 AU AU2016235059A patent/AU2016235059B2/en active Active
- 2016-03-24 EP EP16769690.5A patent/EP3273950A4/en active Pending
- 2016-03-24 MX MX2017012220A patent/MX390860B/es unknown
- 2016-03-24 JP JP2017549691A patent/JP6925277B2/ja active Active
- 2016-03-24 US US15/079,936 patent/US9636397B2/en active Active
- 2016-03-24 WO PCT/US2016/024003 patent/WO2016154432A1/en not_active Ceased
- 2016-03-24 CA CA2979556A patent/CA2979556C/en active Active
-
2017
- 2017-03-23 US US15/467,585 patent/US10265395B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017020175A2 (pt) | 2018-06-12 |
| US10265395B2 (en) | 2019-04-23 |
| AU2016235059A1 (en) | 2017-10-05 |
| MX390860B (es) | 2025-03-21 |
| EP3273950A1 (en) | 2018-01-31 |
| US9636397B2 (en) | 2017-05-02 |
| JP2018510874A (ja) | 2018-04-19 |
| US20170202959A1 (en) | 2017-07-20 |
| CA2979556C (en) | 2023-07-18 |
| AU2016235059B2 (en) | 2021-04-01 |
| WO2016154432A1 (en) | 2016-09-29 |
| NZ735525A (en) | 2024-05-31 |
| EP3273950A4 (en) | 2019-04-24 |
| JP6925277B2 (ja) | 2021-08-25 |
| CA2979556A1 (en) | 2016-09-29 |
| US20160279237A1 (en) | 2016-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017012220A (es) | Composiciones adyuvantes y metodos relacionados. | |
| BR112018008090A2 (pt) | vacina de vírus do herpes simplex. | |
| CL2018001404A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos. | |
| MX2018014573A (es) | Vacuna contra el virus del zika. | |
| MX2018010586A (es) | Nanovacuna de activacion de "sting" para inmunoterapia. | |
| BR112016028961A8 (pt) | fibras eletrotorcidas, seu método de preparação e seu uso, bem como composição, e kit | |
| MX2016016533A (es) | Combinaciones inmunogenas. | |
| PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
| EA201790398A1 (ru) | Способы лечения заболевания печени | |
| AR088820A1 (es) | Moleculas de anticuerpo que tienen especificidad por ox40 humano | |
| BR112013022397A2 (pt) | vacinas combinadas com doses menores de antígeno e/ou adjuvante | |
| AR091316A1 (es) | Moleculas de union humanas que se pueden unir y neutralizar a los virus de la influenza b y sus usos | |
| AR089797A1 (es) | Vacunas contra clostridum difficile que comprenden toxinas recombinantes | |
| MX2020004367A (es) | Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan. | |
| MX2017007187A (es) | Construcciones de anticuerpos de adn y metodo para utilizarlas. | |
| PE20151588A1 (es) | Vacuna contra el virus del dengue | |
| MX2016016746A (es) | Composiciones de vacuna con adyuvante dual, preparacion y usos. | |
| MX385109B (es) | Formulaciones de anticuerpos. | |
| MX381211B (es) | Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia. | |
| BR112017003462A2 (pt) | coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino. | |
| BR112015021523A2 (pt) | composição de uma vacina contra a tosse convulsa acelular, e, métodos para vacinar um sujeito contra a bordetella pertussis e para proteger um sujeito da tosse convulsa | |
| BR112017004197A2 (pt) | composições de vacina contra doenças do vírus da dengue | |
| AR108829A1 (es) | Vacuna contra virus de bronquitis infecciosa | |
| BR112019003992A2 (pt) | vacina contra neisseria meningitidis | |
| UY36617A (es) | Proteínas de fusión inmunogénicas para el tratamiento del cáncer |